Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13808556 | 0.91 | HSD17B10 (0.53) | HSD17B10MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL12039267 | 0.83 | HSD17B10 (0.52) | HSD17B10THRBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13006871 | 0.83 | KDM4E (0.51) | HSD17B10TSHRGAALMNACYP3A4 | |
| SCHEMBL14818934 | 0.81 | GNAI3 (0.48) | HSD17B10SMN1; SMN2TSHRGAALMNA | |
| SCHEMBL26063138 | 0.80 | GAA (0.58) | HSD17B10MEN1KMT2APOLBTSHR | |
| SCHEMBL12141805 | 0.80 | HSD17B10 (0.50) | HSD17B10THRBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26343768 | 0.79 | HSD17B10 (0.44) | HSD17B10MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL12139854 | 0.79 | HSD17B10 (0.49) | HSD17B10THRBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12069692 | 0.79 | GNAI3 (0.46) | HSD17B10KMT2ASMN1; SMN2TSHRGAA | |
| SCHEMBL26307580 | 0.79 | HSD17B10 (0.56) | HSD17B10MEN1KMT2ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC (US) | 2009-06-18 | — | — | US | disclosed |
| US-7405194-B2 | Therapeutic agents and methods of use thereof for the treatment of melanoma | PRAECIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7348307-B2 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-25 | — | — | US | disclosed |
| US-20070254843-A1 | Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | HSD17B10 3658/4885THRB 1518/4885MEN1 693/4885 |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | HSD17B10 3706/4885THRB 3233/4885MEN1 700/4885 |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | HSD17B10 3737/4885THRB 3312/4885MEN1 846/4885 |
| US-20070254843-A1 | Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors | METAP2, ENPEP, METAP1 | HSD17B10 2630/4885THRB 1229/4885MEN1 484/4885 |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | HSD17B10 3658/4885THRB 1518/4885MEN1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.